Progression of non-significant mitral and tricuspid regurgitation after surgical aortic valve replacement for aortic regurgitation

Abstract

Abstract Background There is limited evidence to guide the management of below moderate mitral and tricuspid regurgitation (MR and TR) during surgical aortic valve replacement (SAVR) for aortic regurgitation (AR). We assessed the long-term progression of these valvulopathies. Methods This is a single-center, retrospective analysis encompassing 7.0 (IQR, 3.4-12.1) years of follow-up after consecutive patients undergoing SAVR between 1995 and 2022. Cases with ≥moderate non-aortic valve disorders or congenital heart disease at baseline and those who had undergone prior or concomitant valvular interventions were excluded. The primary outcome was the incidence of ≥moderate MR or TR on the last documented echocardiogram. Results A total of 184 patients (141 (76.6%) males, median age 64 (IQR, 55-74) years, 134 (72.8%) with pure AR) were included. Of them, 46 (25.0%) underwent both SAVR and ascending aortic replacement. On the last echo study, performed at a median of 5.8 (IQR, 2.7-11.0) years after surgery, ≥moderate MR, ≥moderate TR, and either were evident in 20 (10.9%), 25 (13.5%), and 36 (19.6%) individuals, respectively. Of the latter, above moderate MR or TR occurred in 26 (72.2%). Survival rate was lower among patients with ≥moderate MR or TR on the last echocardiogram (47.2% vs 79.7%, p<0.001). After multivariable analysis, a higher risk for the primary outcome was associated with 4 baseline variables: mild to moderate (vs up to mild) MR or TR (OR 4.17, 95% CI 1.35-12.91, p=0.013), clinical heart failure (OR 7.42, 95% CI 3.47-14.82, p=0.004), atrial fibrillation (OR 3.30, 95% CI 1.10-9.85, p=0.033), and use of composite graft (OR 4.20, 95% CI 1.29-13.61, p=0.017). Conversely, echocardiographic measures of biventricular function and dimensions, aortic valve morphology, and surgical urgency were not predictive of the combined endpoint. Conclusion Among patients undergoing SAVR for AR, new significant MR or TR develop in one-fifth by 6 years and may be predicted by baseline clinical and echocardiographic observations.Risk Factors for the Primary Outcome